Tinengotinib in patients with advanced solid tumors harboring actionable FGFR1-3 mutations

被引：0
|
作者：
Piha-Paul, Sarina A.
Liao, Chih-Yi Andy
Fonkoua, Lionel
Mahipa, Amit, I
Goel, Sanjay
Fountzilas, Christos
Shen, Lin
Li, Daneng
Deming, Dustin
Dayyani, Farshid
Han, Weiqing
Niu, Zuoxing
Fan, Jean
Peng, Peng
Wang, Hui
Huang, Peng
Wu, Frank
Javle, Milind
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB162
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Garmezy, B.
    Borad, M.
    Lin, C. C.
    Chen, L. T.
    Perez, C. A.
    Kato, S.
    Tam, B.
    Severson, P.
    Quah, C. S.
    Harding, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
  • [32] Effects of Infigratinib, a Selective FGFR1-3 Tyrosine Kinase Inhibitor, on Dentoalveolar Development
    Aitken, Sarah
    Glover, Omar
    Michel, Zachary
    Chu, Emily
    Avogadri, Francesca
    Martin, David
    Moran, Susan
    Collins, Michael
    Somerman, Martha
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 280 - 280
  • [33] FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors
    Shi, Eileen
    Chmielecki, Juliann
    Tang, Chih-Min
    Wang, Kai
    Heinrich, Michael C.
    Kang, Guhyun
    Corless, Christopher L.
    Hong, David
    Fero, Katherine E.
    Murphy, James D.
    Fanta, Paul T.
    Ali, Siraj M.
    De Siena, Martina
    Burgoyne, Adam M.
    Movva, Sujana
    Madlensky, Lisa
    Heestand, Gregory M.
    Trent, Jonathan C.
    Kurzrock, Razelle
    Morosini, Deborah
    Ross, Jeffrey S.
    Harismendy, Olivier
    Sicklick, Jason K.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [34] FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors
    Eileen Shi
    Juliann Chmielecki
    Chih-Min Tang
    Kai Wang
    Michael C. Heinrich
    Guhyun Kang
    Christopher L. Corless
    David Hong
    Katherine E. Fero
    James D. Murphy
    Paul T. Fanta
    Siraj M. Ali
    Martina De Siena
    Adam M. Burgoyne
    Sujana Movva
    Lisa Madlensky
    Gregory M. Heestand
    Jonathan C. Trent
    Razelle Kurzrock
    Deborah Morosini
    Jeffrey S. Ross
    Olivier Harismendy
    Jason K. Sicklick
    Journal of Translational Medicine, 14
  • [35] FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas
    Picca, Alberto
    Berzero, Giulia
    Bielle, Franck
    Touat, Mehdi
    Savatovsky, Julien
    Polivka, Marc
    Trisolini, Elena
    Meunier, Sheida
    Schmitt, Yohann
    Idbaih, Ahmed
    Khe Hoang-Xuan
    Delattre, Jean-Yves
    Mokhtari, Karima
    Di Stefano, Anna Luisa
    Sanson, Marc
    NEUROLOGY, 2018, 90 (23) : E2086 - E2094
  • [36] Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.
    Cleary, James M.
    Iyer, Gopa
    Oh, Do-Youn
    Mellinghoff, Ingo K.
    Goyal, Lipika
    Ng, Matthew C. H.
    Meric-Bernstam, Funda
    Matos, Ignacio
    Chao, Tsu-Yi
    Sarkouh, Rafik Ait
    Cretegny, Kira
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Vaslin, Anne
    Zanna, Claudio
    Zubel, Angela
    Tabernero, Josep
    Flaherty, Keith
    Hyman, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] A phase 1 dose escalation study of ARQ 751 in adult patients with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3 K mutations, PTEN-null, or other known actionable PTEN mutations
    Pant, S.
    Subbiah, V.
    Rodon, J.
    Janku, F.
    Hong, D.
    Karp, D.
    Piha-Paul, S.
    Tsimberidou, A. M.
    Naing, A.
    Fu, S.
    Savage, R. E.
    Chai, F.
    Yu, Y.
    Tith, K.
    Alfattal, R.
    Schwartz, B.
    Meric-Bernstam, F.
    Yap, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E128 - E128
  • [38] A phase II study of futibatinib (TAS-120) in patients (pts) with advanced (adv) solid tumors harboring fibroblast growth factor receptor (FGFR) genomic aberrations
    Hollebecque, Antoine
    Doi, Toshihiko
    Saavedra, Omar
    Takahashi, Osamu
    He, Helen
    Benhadji, Karim A.
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [39] Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer
    Won, Elizabeth
    Basunia, Azfar
    Chatila, Walid K.
    Hechtman, Jaclyn F.
    Chou, Joanne F.
    Ku, Geoffrey Y.
    Chalasani, Sree B.
    Boyar, Michelle S.
    Goldberg, Zoe
    Desai, Avni M.
    Tuvy, Yaelle
    Berger, Michael F.
    Tang, Laura
    Kelsen, David P.
    Schattner, Mark
    Ilson, David H.
    Capanu, Marinela
    Solit, David B.
    Schultz, Nikolaus
    Janjigian, Yelena Y.
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3811 - 3817
  • [40] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Harding, James J.
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Garmezy, Benjamin
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS637 - TPS637
12345